As a result of the complex and multi-systemic involvement of cystic fibrosis (CF) and the need for care by specialists, treatment, and follow-up care at specialty centers with multidisciplinary care teams (i.e., cystic fibrosis centers) is recommended. There’s no cure for cystic fibrosis, but medications and other therapies can ease symptoms, reduce complications, and improve quality of life. Close monitoring and early, aggressive intervention are recommended to slow the progression of CF, which can lead to a longer life
Medications used to treat patients with cystic fibrosis market may include pancreatic enzyme supplements, multivitamins (particularly fat-soluble vitamins), mucolytics, antibiotics (including inhaled, oral, or parenteral), bronchodilators, anti-inflammatory agents, and CFTR potentiators (e.g., ivacaftor) and correctors (e.g., elexacaftor, lumacaftor, tezacaftor). The drugs marketed for CFTR correctors are TRIKAFTA, SYMDEKO, ORKAMBI and KALYDECO.
A normal diet with additional energy and unrestricted fat intake is recommended. A high-energy and high-fat diet, in addition to supplemental vitamins (especially fat-soluble) and minerals, is recommended to compensate for malabsorption and the increased energy demand of chronic inflammation. Additional salt intake is recommended for patients living in hot climates, especially during exercise or activities that cause excessive sweating. Regular exercise increases physical fitness in patients with cystic fibrosis.
Hypertonic saline inhalation has been proposed as a therapy to increase hydration of airway surface liquid in patients with CF. The Pulmonary Therapies Committee of Cystic Fibrosis Foundation recommends long-term use of hypertonic saline for patients with cystic fibrosis aged 6 or older to improve lung function and to reduce the number of exacerbations.
Check it's- Cystic Fibrosis Market Report
DelveInsight’s analysts estimate that the market is expected to show positive growth, mainly attributed to increased number of cases and the expected launch of MRT5005 (Translate Bio), PTI-808/PTI-801/PTI-428 (Proteostasis Therapeutics and others during the forecast period [2017-2030]. These therapies are novel in nature and their approval will have tremendous effects on the future.
In the coming days, the competitive landscape for the Cystic Fibrosis (CF) market is set to change due to improvement in the diagnosis methodologies, raising awareness of the diseases, and incremental healthcare spending across the world. Through the principles developed with the CF care centers of multidisciplinary, multisystem preventative care, significant advances in survival, and improved quality of life has occurred over these 60 years.